A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Authors: Phillips, Tycel J., Avigdor, Abraham, Gurion, Ronit, Patti, Caterina, Corradini, Paolo, Tani, Monica, Mehta, Amitkumar, Lossos, Izidore S., Zinzani, Pier Luigi, Thieblemont, Catherine, Jurczak, Wojciech, Zheng, Fred, Rappold, Erica, Zhao, Wanying, Jiang, Ping, Johnson, Peter

Source: In Blood Advances 27 February 2024 8(4):867-877

Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies

Authors: Patel, Manish R., Donnellan, William, Byrne, Michael, Asch, Adam S., Zeidan, Amer M., Baer, Maria R., Fathi, Amir T., Kuykendall, Andrew T., Zheng, Fred, Walker, Chris, Cheng, Lulu, Marando, Cindy, Savona, Michael R.

Source: Clinical lymphoma, myeloma & leukemia. 23(9):674-686

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100195841320.0x000001&indx=1&recIds=ETOCvdc_100195841320.0x000001

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

Authors: Trněný, Marek, Avigdor, Abraham, McKinney, Matthew S., Paneesha, Shankara, Wahlin, Björn E., Hrom, John S., Cunningham, David, Morley, Nicholas, Canales, Miguel, Bastos-Oreiro, Mariana, Belada, David, Devizzi, Liliana, Zheng, Fred, DeMarini, Douglas J., Jiang, Wei, Jiang, Ping, Lynch, Ryan C.

Source: In eClinicalMedicine September 2023 63

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

Authors: Zinzani, Pier Luigi, Trněný, Marek, Ribrag, Vincent, Zilioli, Vittorio Ruggero, Walewski, Jan, Christensen, Jacob Haaber, Delwail, Vincent, Rodriguez, Guillermo, Venugopal, Parameswaran, Coleman, Morton, Dartigeas, Caroline, Patti, Caterina, Pane, Fabrizio, Jurczak, Wojciech, Taszner, Michal, Paneesha, Shankara, Zheng, Fred, DeMarini, Douglas J., Jiang, Wei, Gilmartin, Aidan, Mehta, Amitkumar

Source: In eClinicalMedicine August 2023 62

Bromodomain and extra-terminal inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE

Authors: Pearson, Andrew DJ., DuBois, Steven G., Buenger, Vickie, Kieran, Mark, Stegmaier, Kimberly, Bandopadhayay, Pratiti, Bennett, Kelly, Bourdeaut, Franck, Brown, Patrick A., Chesler, Louis, Clymer, Jessica, Fox, Elizabeth, French, Christopher A., Germovsek, Eva, Giles, Francis J., Bender, Julia G., Hattersley, Maureen M., Ludwinski, Donna, Luptakova, Katarina, Maris, John, McDonough, Joe, Nikolova, Zariana, Smith, Malcolm, Tsiatis, Athanasios C., Vibhakar, Rajeev, Weiner, Susan, Yi, Joanna S., Zheng, Fred, Vassal, Gilles

Source: In European Journal of Cancer March 2021 146:115-124

MPN-559 Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 (LIMBER-103) in Patients With Relapsed or Refractory Myelofibrosis (R/R MF) and Other Advanced Myeloid Neoplasms: A Phase I Study

Authors: Watts, Justin, Hunter, Anthony, Iurlo, Alessandra, Xicoy, Blanca, Palandri, Francesca, Reeves, Brandi, Vannucchi, Alessandro, Bose, Prithviraj, Diaz, Rosa, Halpern, Anna, Chen, Xuejun, Burke, Lea, Zhou, Feng, Zheng, Fred, Vachhani, Pankit

Source: Clinical lymphoma, myeloma & leukemia. 23(S1):S403-S404

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100196312834.0x000001&indx=1&recIds=ETOCvdc_100196312834.0x000001

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Authors: Flinn, Ian W., Bartlett, Nancy L., Blum, Kristie A., Ardeshna, Kirit M., LaCasce, Ann S., Flowers, Christopher R., Shustov, Andrei R., Thress, Kenneth S., Mitchell, Patrick, Zheng, Fred, Skolnik, Jeffrey M., Friedberg, Jonathan W.

Source: In European Journal of Cancer February 2016 54:11-17

POSTER: MPN-559 Bromodomain and Extra-terminal (BET) Inhibitor INCB057643 (LIMBER-103) in Patients With Relapsed or Refractory Myelofibrosis (R/R MF) and Other Advanced Myeloid Neoplasms: A Phase I Study

Authors: Watts, Justin, Hunter, Anthony, Iurlo, Alessandra, Xicoy, Blanca, Palandri, Francesca, Reeves, Brandi, Vannucchi, Alessandro, Bose, Prithviraj, Diaz, Rosa, Halpern, Anna, Chen, Xuejun, Burke, Lea, Zhou, Feng, Zheng, Fred, Vachhani, Pankit

Source: Clinical lymphoma, myeloma & leukemia. 23(S1):S196-S196

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100196318847.0x000001&indx=1&recIds=ETOCvdc_100196318847.0x000001

MPN-112 Bromodomain and Extra-terminal (BET) Inhibitor INCB057643 in Patients With Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Authors: Vachhani, Pankit, Vannucchi, Alessandro M., Hunter, Anthony M., McMahon, Brandon, Tantravahi, Srinivas K., Iurlo, Alessandra, Xicoy, Blanca, Palandri, Francesca, Searle, Emma, Reeves, Brandi, Bose, Prithviraj, Ayala Diaz, Rosa, Halpern, Anna B., Chen, Xuejun, Burke, Lea, Zhou, Feng, Zheng, Fred, Watts, Justin

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S415-S415

Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 in Patients With Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Authors: Vachhani, Pankit, Vannucchi, Alessandro M., Hunter, Anthony M., McMahon, Brandon, Tantravahi, Srinivas K., Iurlo, Alessandra, Xicoy, Blanca, Palandri, Francesca, Searle, Emma, Reeves, Brandi, Bose, Prithviraj, Ayala Diaz, Rosa, Halpern, Anna B., Chen, Xuejun, Burke, Lea, Zhou, Feng, Zheng, Fred, Watts, Justin

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S199-S199

Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Authors: Watts, Justin M., Vannucchi, Alessandro M., Hunter, Anthony M., McMahon, Brandon, Tantravahi, Srinivas K., Iurlo, Alessandra, Xicoy, Blanca, Palandri, Francesca, Searle, Emma, Reeves, Brandi N., Bose, Prithviraj, Ayala, Rosa, Halpern, Anna B., Chen, Xuejun, Burke, Lea M, Zhou, Feng, Zheng, Fred, Vachhani, Pankit

Source: In Blood 2 November 2023 142 Supplement 1:750-750

INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study

Authors: Watts, Justin ^*, Hunter, Anthony M. ^*, Iurlo, Alessandra ^*, Xicoy, Blanca ^*, Palandri, Francesca ^*, Reeves, Brandi, Vannucchi, Alessandro M. ^*, Chen, Xuejun ^*, Seguy, Francis ^*, Zhou, Feng ^*, Zheng, Fred ^*, Vachhani, Pankit ^*

Source: In Blood 15 November 2022 140 Supplement 1:9696-9697

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

Authors: Lynch, Ryan C., Avigdor, Abraham, McKinney, Matthew S, Paneesha, Shankara, Wahlin, Björn, Hrom, John S, Cunningham, David, Morley, Nicholas, Canales, Miguel, Bastos-Oreiro, Mariana, Belada, David, Devizzi, Liliana, Zheng, Fred, DeMarini, Douglas J, Jiang, Wei, Trněný, Marek

Source: In Blood 23 November 2021 138 Supplement 1:813-813

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205)

Authors: Mehta, Amitkumar, Trněný, Marek, Walewski, Jan, Ribrag, Vincent, Dartigeas, Caroline, Christensen, Jacob Haaber, Pane, Fabrizio, Rodriguez, Guillermo, Taszner, Michal, Venugopal, Parameswaran, Zilioli, Vittorio Ruggero, Zheng, Fred, DeMarini, Douglas J, Jiang, Wei, Zinzani, Pier Luigi Luigi

Source: In Blood 23 November 2021 138 Supplement 1:382-382

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Authors: Phillips, Tycel, Avigdor, Abraham, Gurion, Ronit, Patti, Caterina, Corradini, Paolo, Tani, Monica, Mehta, Amitkumar, Lossos, Izidore S., Zinzani, Pier Luigi Luigi, Thieblemont, Catherine, Jurczak, Wojciech, Zheng, Fred, Rappold, Erica, Zhao, Wanying, Johnson, Peter

Source: In Blood 23 November 2021 138 Supplement 1:44-44

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Authors: Lynch, Ryan C. ^*, Paneesha, Shankara, Avigdor, Abraham, McKinney, Matthew S ^*, Wahlin, Björn E, Hrom, John S ^*, Belada, David ^*, Canales, Miguel ^*, Cunningham, David ^*, Devizzi, Liliana ^*, Morley, Nicholas ^*, Zheng, Fred ^*, DeMarini, Douglas J ^*, Jiang, Wei ^*, Trněný, Marek

Source: In Blood 5 November 2020 136 Supplement 1:36-37

A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103)

Authors: Lihou, Christine ^*, Zhou, Gongfu ^*, Zheng, Fred ^*

Source: In Blood 5 November 2020 136 Supplement 1:16-17

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)

Authors: Mehta, Amitkumar, Trněný, Marek, Walewski, Jan ^*, Ribrag, Vincent, Dartigeas, Caroline ^*, Christensen, Jacob Haaber ^*, Pane, Fabrizio, Rodríguez, Guillermo ^*, Taszner, Michal ^*, Venugopal, Parameswaran, Zilioli, Vittorio Ruggero ^*, Zheng, Fred ^*, DeMarini, Douglas J ^*, Jiang, Wei ^*, Zinzani, Pier Luigi

Source: In Blood 5 November 2020 136 Supplement 1:22-23

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Authors: Zinzani, Pier Luigi, Delwail, Vincent ^*, Paneesha, Shankara, Rule, Simon ^*, Martin Garcia-Sancho, Alejandro ^*, Marin-Niebla, Ana ^*, Salles, Gilles, Sancho, Juan-Manuel ^*, Vergote, Vibeke ^*, Zilioli, Vittorio Ruggero ^*, Zheng, Fred ^*, DeMarini, Douglas J ^*, Jiang, Wei ^*, Mehta, Amitkumar

Source: In Blood 5 November 2020 136 Supplement 1:43-44

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Authors: Phillips, Tycel J., Corradini, Paolo, Gurion, Ronit ^*, Patti, Caterina ^*, Tani, Monica ^*, Avigdor, Abraham, Jurczak, Wojciech, Mehta, Amitkumar, Zinzani, Pier Luigi, Lossos, Izidore S., Thieblemont, Catherine, Zheng, Fred ^*, Rappold, Erica ^*, Zhao, Wanying ^*, Johnson, Peter

Source: In Blood 5 November 2020 136 Supplement 1:27-28